Message from
our Management team.
Thank you for visiting our website and taking an interest in our mission to improve lives blighted by depression and other mental health conditions – making patients feel better and enabling them to lead happier, more fulfilling and productive lives as a result.
Neurocentrx aims to provide our ketamine oral formulations to depression patients worldwide, assisting them in their journey to recover from this debilitating condition that can be caused by so many different factors.
First, we must test our formulations in clinical trials worldwide to prove they work.
We are always keen to talk to investors to support our growth plans and help us launch our products worldwide. We have great partners working with us to deliver our plans and you can discover more on our Testimonials page.
Key Figures.
£4m investment since 2014
Successful Phase 1 trial
Many product applications and uses
Multiple dose level
2 patents
25-plus years sector experience within the senior team
King’s College
“Working with Neurocentrx has been a most rewarding experience.
“They bring a combination of enthusiasm, professionalism, scientific rigour and sound business sense to projects.
“I really look forward to working with them in the future.”
Professor Allan Young,
Head of School, Academic Psychiatry.
Director, Centre for Affective Disorders,
Institute of Psychiatry, Psychology and Neuroscience (IoPPN)
King’s College London.
Caritas Science Solutions
“It has been a privilege working with the lovely team at Neurocentrx from the start of their journey into clinic, and a joy to have grown and shared successes together over the last couple of years.
“We are proud to support a company which shares our vision and passion to make a difference in mental health, and we look forward to seeing the immense impact they will have in years to come.”
Leigh Fell,
Chief Executive Officer,
Caritas Science Solutions.
DataMagik
“Neurocentrx’s clear communication throughout the trial has been invaluable in making the set-up and running of the trial go smoothly. The team is friendly, personable and respond to any queries in a timely manner.”
DataMagik.
Rapport
“Rapport has been working with the Neurocentrx team as its regulatory partner for six months now.
“They have been very clear regarding their ambitions and accepting of advice and support where needed. We have moved forward very quickly and professionally so that Neurocentrx have the direction they need.”
Lorna Griffin,
Chief Executive Officer,
Rapport.